Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendrosomal nanocurcumin
- Development stage
- Unknown
- Lead developer
- Tarbiat Modares University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
Dendrosomal nanocurcumin (DNC) is a nanoparticle-based formulation of curcumin, a natural polyphenol derived from *Curcuma longa*. This formulation utilizes a non-toxic, biodegradable dendrosomal nanocarrier—typically composed of oleic acid and polyethylene glycol (PEG)—to overcome the inherent pharmacological limitations of curcumin, such as its poor aqueous solubility, low stability, and minimal systemic bioavailability. DNC has demonstrated significant therapeutic potential in oncology by inducing apoptosis and downregulating the expression of matrix metalloproteinases (MMPs), specifically MMP-2 and MMP-9, which are critical for tumor invasion and metastasis. Beyond its anticancer properties, DNC has been investigated for its anti-inflammatory and antioxidant effects, including clinical evaluation for its ability to modulate cytokine storms in inflammatory conditions such as COVID-19.
- Other names
- dendrosomal curcuminnano-curcuminnanocurcumin
02
Targets
BCL-2 (BCL-2 family)EZH2 (Histone-lysine N-methyltransferase EZH2)DANCR (Differentiation antagonizing non-protein coding RNA)CASP3 (Caspase-3)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)NF-κB
Beyond the preview
Go deeper on dendrosomal nanocurcumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendrosomal nanocurcumin.